Rapamycin Press
Life extension in our lifetime

Mikhail Blagosklonny, MD, PhD
Executive Editor and Chair

We provide financial support for clinical research on rapamycin and other anti-aging drugs.

Rapamycin Press co-publishes journal Aging, supports virtual conferences, helps to launch new journals, donates to anti-aging trials, invests in anti-aging biotech and awards outstanding publications.

Announcement: November 14, 2020.
Rapamycin Press donates $25,000 to Dr. Alan Green for Prevention of Alzheimer’s disease by Rapamycin in ApoE4 homozygous patients

Announcement: October 8, 2020.
Rapamycin Press has donated $50,000 to support clinical trial PEARL (the Participatory Evaluation of Aging with Rapamycin for Longevity) by AgelessRx